Key Highlights

● Aardvark Therapeutics shares have fallen sharply, most recently closing at $5.89, down 12.74%, near the bottom of a 52-week range of about $3.35 to $17.94.

● The company terminated its Phase 3 HERO trial and open-label extension for ARD-101 in Prader-Willi syndrome hyperphagia in June 2026 after the program was placed under an FDA clinical hold.

● Multiple plaintiffs' firms announced securities class actions against the company following the clinical setback.

● As of June 30, 2026, Aardvark held cash of $73.9 million, which management says funds operations into late 2027 while the company analyzes unblinded HERO trial data for potential next steps.

Aardvark Therapeutics (NASDAQ:AARD) has spent much of 2026 as a cautionary tale in small-cap biotech. The San Diego-based company, which completed its initial public offering only in early 2025, has watched its shares slide toward the low single digits after the collapse of the clinical program that underpinned its valuation. By the close on 20 August 2026 the stock changed hands around $6.03, down roughly 11% on the day, sitting near the bottom of a 52-week range that runs from about $3.35 to $17.94. The company's market Capitalization has compressed to roughly $132 million, a fraction of where it stood shortly after its debut.

The proximate reason AARD screens as a notable decliner is not a single fresh headline but the accumulation of negative developments around its lead asset, compounded most recently by the emergence of securities litigation. Beginning around 17--18 August 2026, multiple plaintiffs' firms, among them Holzer & Holzer, Hagens Berman, Levi & Korsinsky, Robbins LLP and Bronstein, Gewirtz & Grossman, issued investor alerts announcing that a securities class action had been filed against the company, encouraging shareholders with losses to come forward. Such filings are routine after a sharp drug-development setback, but the wave of alerts has kept selling pressure and negative sentiment fresh in the days leading into the 21 August snapshot.

The ARD-101 setback

The core of the story is ARD-101, an orally administered small-molecule candidate that Aardvark was advancing for hyperphagia, the persistent, distressing hunger, associated with Prader-Willi syndrome (PWS), a rare genetic disorder. ARD-101 was the company's most advanced program and the centerpiece of its Investment thesis, tested in the Phase 3 HERO trial.

The trajectory turned sharply negative early in the year. In late February 2026, Aardvark announced a voluntary pause of the Phase 3 HERO study. According to the company's own second-quarter disclosures, the program was subsequently placed under an FDA clinical hold, and in June 2026 Aardvark terminated both the HERO trial and its open-label extension. Management stated that it does not currently intend to resume these studies as previously designed. That sequence effectively removed the near-term catalyst that had supported the stock and reset expectations for the entire company.

Aardvark has said it is analyzing unblinded data from the terminated studies during the third quarter of 2026 to determine potential next steps, and that it remains in active discussions with the FDA to support resolution of the clinical hold. Those are forward-looking processes with uncertain outcomes; the company has not disclosed conclusions from the FDA dialogue, and investors are being asked to wait for clarity on whether any version of the ARD-101 program can be salvaged.

The financial picture

Aardvark reported its second-quarter 2026 results on 11 August 2026. The company ended the quarter with cash and equivalents of $73.9 million as of 30 June 2026, down from $91.2 million at the end of March. Management characterized its runway as sufficient to fund operations into late 2027. The net loss for the quarter was $14.4 million, essentially unchanged from the year-earlier period. Research and Development expense fell to $10.5 million, a decline of $2.7 million year over year that is consistent with a wound-down late-stage trial, while general and administrative expense rose to $4.6 million, up $1.9 million from a year earlier.

For a pre-revenue biotech, the Balance Sheet is the lifeline, and here the message is mixed. A runway into late 2027 gives the company time, but with its flagship program halted, the question is whether that capital funds a credible path forward or simply extends a search for a new strategic direction. Cash that once looked like fuel for a pivotal readout now looks like a cushion for a company reassessing its reason for being.

Why investors are concerned

The concern is straightforward: the asset that justified Aardvark's public-market valuation is no longer progressing on its expected timeline, and there is no confirmed replacement catalyst. Rare-disease programs like PWS hyperphagia are attractive precisely because they target conditions with high unmet need and potential regulatory incentives, but that same concentration means a single clinical hold can dominate the Equity story. Secondary coverage has noted that analyst sentiment deteriorated as the setback unfolded, with reduced price targets and at least one downgrade to a bearish rating following the clinical-hold news earlier in 2026; investors should treat specific target figures cited in third-party summaries as market commentary rather than company-confirmed guidance.

Layered on top is the litigation overhang. Securities class actions of this type typically allege that a company or its executives made statements about a program's prospects that later proved misleading in light of the setback. Whatever their eventual merits, these suits introduce legal cost and headline risk, and their arrival often coincides with, and reinforces, weakness in the underlying shares.

What to watch next

Several markers will determine whether Aardvark stabilizes or continues to erode. The most important is the outcome of its third-quarter analysis of the unblinded HERO and open-label data: whether that review points to a redesigned trial, a different patient population or dosing approach, or a decision to shelve ARD-101 altogether. Equally important is any concrete update from the FDA discussions regarding the clinical hold, since resolution, or the lack of it, frames every other decision.

Beyond the lead program, watch for signals about capital allocation and strategic direction. With a runway into late 2027 and a halted flagship, management faces choices about whether to preserve cash, pursue Business development, or advance earlier-stage assets. Any commentary on the securities litigation, and on whether additional programs can move into the spotlight, will also matter.

The working headline asks whether Wall Street is losing its appetite for AARD. The verifiable record shows a lead program under FDA hold and terminated as designed, a diminished valuation, and newly filed Shareholder litigation. What has not been established is a positive path back, and until Aardvark provides one, the burden of proof sits squarely with the company.